BillionToOne, Inc. vs RadNet, Inc., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where BLLN and RDNT diverge most: on net margin, BLLN reads 8.6% and RDNT reads -0.9%; on return on equity, BLLN reads 5.9% and RDNT reads -1.5%. The rest of the comparable metrics sit closer together. What RDNT's price implies is a somewhat stretched bet versus history (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | BLLN | RDNT |
|---|---|---|
| Price | $98.15 | $70.96 |
| Market cap | $5.3B | $5.6B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Growth |
| P/E | 172.2 | — |
| P/B | 9.96 | 4.01 |
| P/S | 14.53 | 2.46 |
| EV/EBITDA | 127.4 | 25.6 |
| Revenue growth | +88.5% | +18.8% |
| Gross margin | 70.5% | — |
| Operating margin | 5.0% | 6.3% |
| Net margin | 8.6% | -0.9% |
| Return on equity | 5.9% | -1.5% |
| Return on assets | 4.3% | -0.5% |
| Return on invested capital | 4.6% | 2.0% |
| FCF yield | 0.6% | 1.3% |
| Debt / equity | 0.17 | 0.96 |
| Current ratio | 11.69 | 1.48 |
| Altman Z (solvency) | 7.03 | 1.81 |
| Piotroski F (quality) | 6 / 9 | 5 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.